Subscribe
Facebook Twitter Instagram Youtube

WHA CEO, Cary James appointed as Civil Society Representative to the UHC2030 Steering Committee

World Hepatitis Alliance (WHA) CEO, Cary James, has been appointed to the UHC2030 international health partnership steering committee, the global platform building stronger health systems for universal health coverage (UHC). Cary will represent civil society organisations on the steering committee for four years.  

On his appointment, Cary James said, “I’m thrilled to be joining the UHC2030 steering committee and representing the important voices of civil society organisations. If we are to achieve the UHC goals of accessible, affordable healthcare to all by 2030, then civil society has an important role to play, both in terms of advocacy and implementation.  I look forward to working with the steering committee over the next four years to accelerate progress towards UHC2030.”

Cary has been serving as a member of the UHC2030 Civil Society Engagement Mechanism (CSEM) Advisory Group since 2019. The same year, the United Nations (UN) Political Declaration on UHC was signed at the UN General Assembly. WHA, its members and partners successfully advocated for the inclusion of viral hepatitis in the Political Declaration, marking another vital political commitment towards hepatitis elimination.

Read more about Cary’s appointment on the CSEM for UHC 2030 website here

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)
Confirm consent(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close